Previous work has described that sPD1 enhanced anti-tumor immunity by blocking PD-L1 in tumor cells [16], whereas sPD-L1 predicted poor prognosis in aggressive diffuse large B-Cell lymphoma [8]. Here, HOXD13 is linked to neoplasm.